Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; and (xiii) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31
'/>"/>
SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... - EastMed Inc., the medical manufacturing company that caters ... clearance to market its flagship product, uresta(TM) Continence Care, ... to get the official word from the FDA," said ... (TM) Continence Care offers an innovative and cost-effective option ...
... Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced ... the XIAP antisense oligonucleotide, AEG35156, will be highlighted in ... the American Society of Hematology (ASH) in San Francisco, ... presentation is entitled "Phase I/II Trial of the XIAP ...
... a business unit of DSM Pharmaceutical Products, and Dutch,biotechnology company ... today announced that Hungary-based Gedeon Richter Plc. signed a,commercial license ... the PER.C6(R) platform. , ... About PER.C6(R) technology , ...
Cached Biology Technology:Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 2DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 4
(Date:4/14/2014)... David Kisailus, the Winston Chung Endowed Chair ... Riverside,s Bourns College of Engineering, has been named ... scientists selected by the advisory board of the ... Sciences and organizers of the Kavli/National Academy of ... Foundation, which is based in Oxnard, supports scientific ...
(Date:4/14/2014)... you feel when an elevator zips you up multiple floors ... elevator carried you all the way up to the top ... , That,s similar to what many fish experience when they ... the change in pressure is simply too big, too fast, ... article in the March issue of the journal Fisheries ...
(Date:4/14/2014)... Chicago,s Field Museum and international collaborators have reconstructed the ... the New World tropics, the region of the Earth ... nuclear DNA sequences uncovered three species new to science, ... Since 1960, when modern studies on this group began, ... 22. The newest additions were described in a ...
Breaking Biology News(10 mins):Professor receives young scientist honor 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5Three new species of yellow-shouldered bats discovered in museum collections 2Three new species of yellow-shouldered bats discovered in museum collections 3
... to new research funded by the Economic and Social ... Open University, led by Professor Andy Lane, has taken ... not those mainly involved in organic growing - ... and the food industry regard GM, but this is ...
... is the ultimate destination for anyone interested in natural history ... broadly about our responsibilities to all life on Earth. Thats ... and the Environment at The University of Nottingham, who has ... Observer for the International Association of Antarctica Tour Operators (IAATO). ...
... Now think of bacteria eating rock below the ocean ... 15,000 feet underwater" With a $3.9 million grant ... Katrina Edwards will lead a first-of-its-kind drilling expedition to ... which live on chemical reactions with rock and water, ...
Cached Biology News:What farmers think about GM crops 2Observing sustainable tourism in Antarctica 2Observing sustainable tourism in Antarctica 3USC awarded $3.9M for lab under the sea 2
In plasmid or lambda vector. Please inquire for more details!...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
... SARA ( Abpromise for all tested ... peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding ... (Drosophila melanogaster) SARA. Conserved sequence unique ... ID: 9372 Swiss ...
Biology Products: